世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

オンコロジーアポトーシスモジュレーターの世界市場成長率 2023-2029


Global Oncology Apoptosis Modulator Market Growth 2023-2029

オンコロジーアポトーシスモジュレーターの世界市場規模は、2022年の3815.2百万米ドルから2029年には8128.5百万米ドルに成長すると予測され、2023年から2029年までのCAGRは11.4％と予測されています。 オンコロ... もっと見る

　

　

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション 		2023年6月14日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら 		105 英語

　

サマリー

オンコロジーアポトーシスモジュレーターの世界市場規模は、2022年の3815.2百万米ドルから2029年には8128.5百万米ドルに成長すると予測され、2023年から2029年までのCAGRは11.4％と予測されています。
オンコロジーアポトーシスモジュレーターの米国市場は、2023年から2029年までのCAGRで、2022年の100万米ドルから2029年には100万米ドルに増加すると予測されています。
オンコロジーアポトーシスモジュレーターの中国市場は、2023年から2029年までのCAGR %で、2022年の百万米ドルから2029年には百万米ドルに増加すると推定されます。
オンコロジーアポトーシスモジュレーターのヨーロッパ市場は、2023年から2029年までのCAGR %で、2022年の百万米ドルから2029年には百万米ドルに増加すると推定されます。
世界の主要なオンコロジーアポトーシスモジュレーターのプレーヤーは、EpiCept Corporation、Novartis Ltd.、Pfizer Inc.、Pharmacyclics、ISIS Pharmaceutical Inc.、Abbott Laboratories、Genta Inc、Amgen Inc、Anavex Life Sciences Corporationなどです。収益面では、世界の2大企業が2022年にほぼ％のシェアを占めています。
オンコロジーアポトーシスモジュレーターは、細胞死やアポトーシスに重要な役割を果たすBH3様タンパク質である。癌抑制タンパク質であるRas association domain family 1A (RASSF1A)の重要なパートナーであり、Bcl-2ファミリーのプロアポトーシスタンパク質Baxを活性化する機能があります。
LPI（LPインフォメーション）の最新リサーチレポート「オンコロジー・アポトーシスモジュレーターの業界予測」は、過去の販売実績と2022年の世界のオンコロジー・アポトーシスモジュレーターの総販売実績を調べ、2023年から2029年の予想オンコロジー・アポトーシスモジュレーター販売について地域と市場分野ごとに包括的に分析しています。オンコロジーアポトーシスモジュレータの売上を地域別、市場分野別、サブセクター別に分類し、世界のオンコロジーアポトーシスモジュレータ産業の詳細な分析（百万米ドル単位）を提供します。
本インサイトレポートでは、世界のオンコロジーアポトーシスモジュレーターの状況を包括的に分析し、製品区分、会社設立、収益、市場シェア、最新開発、M&A活動に関する主要動向を明らかにします。また、本レポートでは、加速する世界のオンコロジーアポトーシスモジュレーター市場におけるこれらの企業の独自のポジションをより良く理解するために、オンコロジーアポトーシスモジュレーターのポートフォリオと能力、市場参入戦略、市場ポジション、地理的フットプリントに焦点を当てて、主要グローバル企業の戦略を分析しています。
本インサイトレポートでは、オンコロジーアポトーシスモジュレーターの世界的な見通しを形成する主要な市場動向、推進要因、影響要因を評価し、アポトーシス経路別、アプリケーション別、地域別、市場規模別に予測を細分化して、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの定性的・定量的な市場インプットに基づく透明性の高い手法により、本調査予測は、世界のオンコロジーアポトーシスモジュレーターの現状と将来の軌道について非常にニュアンスのある見方を提供します。
本レポートでは、製品アポトーシス経路、用途、主要メーカー、主要地域・国別のオンコロジーアポトーシスモジュレーター市場の包括的な概要、市場シェア、成長機会について紹介します。
市場のセグメンテーション
アポトーシス経路別セグメンテーション
外来性パスウェイ
内在性パスウェイ（Intrinsic Pathway
アプリケーション別セグメンテーション
病院薬局
小売薬局
オンライン薬局
また、本レポートでは、地域別に市場を分割しています：
米州
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
欧州
ドイツ
フランス
イギリス
イタリア
ロシア
中近東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、主要な専門家から収集した情報、企業のカバレッジ、製品ポートフォリオ、市場浸透度を分析した上で選定されています。
エピセプト株式会社
ノバルティス社
ファイザー株式会社
ファーマシークリックス
アイシス・ファーマシューティカル・インク
アボット・ラボラトリーズ
ジェンタ・インク
アムジェン社
アナベックスライフサイエンス株式会社
インフィニティ・ファーマシューティカルズInc.
ArQule Inc.
アントレメッド・インク
セラプトシスSA
アポプロジック・ファーマシューティカルズ・インク（ApopLogic Pharmaceuticals Inc
本レポートで扱う主な質問
世界の腫瘍アポトーシスモジュレーター市場の10年後の展望は？
世界および地域別に、腫瘍アポトーシスモジュレーターの市場成長を促進する要因は何か？
市場別、地域別に最も急成長するのはどの技術か？
オンコロジーアポトーシスモジュレーターの市場機会は、エンドマーケットの規模によってどのように変化するのか？
オンコロジーアポトーシスモジュレーターはアポトーシス経路、アプリケーションをどのように分類しているのか？
COVID-19とロシア・ウクライナ戦争の影響とは？


ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oncology Apoptosis Modulator Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Oncology Apoptosis Modulator by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Oncology Apoptosis Modulator by Country/Region, 2018, 2022 & 2029
2.2 Oncology Apoptosis Modulator Segment By Apoptotic Pathway
2.2.1 Extrinsic Pathway
2.2.2 Intrinsic Pathway
2.3 Oncology Apoptosis Modulator Sales By Apoptotic Pathway
2.3.1 Global Oncology Apoptosis Modulator Sales Market Share By Apoptotic Pathway (2018-2023)
2.3.2 Global Oncology Apoptosis Modulator Revenue and Market Share By Apoptotic Pathway (2018-2023)
2.3.3 Global Oncology Apoptosis Modulator Sale Price By Apoptotic Pathway (2018-2023)
2.4 Oncology Apoptosis Modulator Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Oncology Apoptosis Modulator Sales by Application
2.5.1 Global Oncology Apoptosis Modulator Sale Market Share by Application (2018-2023)
2.5.2 Global Oncology Apoptosis Modulator Revenue and Market Share by Application (2018-2023)
2.5.3 Global Oncology Apoptosis Modulator Sale Price by Application (2018-2023)
3 Global Oncology Apoptosis Modulator by Company
3.1 Global Oncology Apoptosis Modulator Breakdown Data by Company
3.1.1 Global Oncology Apoptosis Modulator Annual Sales by Company (2018-2023)
3.1.2 Global Oncology Apoptosis Modulator Sales Market Share by Company (2018-2023)
3.2 Global Oncology Apoptosis Modulator Annual Revenue by Company (2018-2023)
3.2.1 Global Oncology Apoptosis Modulator Revenue by Company (2018-2023)
3.2.2 Global Oncology Apoptosis Modulator Revenue Market Share by Company (2018-2023)
3.3 Global Oncology Apoptosis Modulator Sale Price by Company
3.4 Key Manufacturers Oncology Apoptosis Modulator Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oncology Apoptosis Modulator Product Location Distribution
3.4.2 Players Oncology Apoptosis Modulator Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Oncology Apoptosis Modulator by Geographic Region
4.1 World Historic Oncology Apoptosis Modulator Market Size by Geographic Region (2018-2023)
4.1.1 Global Oncology Apoptosis Modulator Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Oncology Apoptosis Modulator Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Oncology Apoptosis Modulator Market Size by Country/Region (2018-2023)
4.2.1 Global Oncology Apoptosis Modulator Annual Sales by Country/Region (2018-2023)
4.2.2 Global Oncology Apoptosis Modulator Annual Revenue by Country/Region (2018-2023)
4.3 Americas Oncology Apoptosis Modulator Sales Growth
4.4 APAC Oncology Apoptosis Modulator Sales Growth
4.5 Europe Oncology Apoptosis Modulator Sales Growth
4.6 Middle East & Africa Oncology Apoptosis Modulator Sales Growth
5 Americas
5.1 Americas Oncology Apoptosis Modulator Sales by Country
5.1.1 Americas Oncology Apoptosis Modulator Sales by Country (2018-2023)
5.1.2 Americas Oncology Apoptosis Modulator Revenue by Country (2018-2023)
5.2 Americas Oncology Apoptosis Modulator Sales By Apoptotic Pathway
5.3 Americas Oncology Apoptosis Modulator Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oncology Apoptosis Modulator Sales by Region
6.1.1 APAC Oncology Apoptosis Modulator Sales by Region (2018-2023)
6.1.2 APAC Oncology Apoptosis Modulator Revenue by Region (2018-2023)
6.2 APAC Oncology Apoptosis Modulator Sales By Apoptotic Pathway
6.3 APAC Oncology Apoptosis Modulator Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Oncology Apoptosis Modulator by Country
7.1.1 Europe Oncology Apoptosis Modulator Sales by Country (2018-2023)
7.1.2 Europe Oncology Apoptosis Modulator Revenue by Country (2018-2023)
7.2 Europe Oncology Apoptosis Modulator Sales By Apoptotic Pathway
7.3 Europe Oncology Apoptosis Modulator Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oncology Apoptosis Modulator by Country
8.1.1 Middle East & Africa Oncology Apoptosis Modulator Sales by Country (2018-2023)
8.1.2 Middle East & Africa Oncology Apoptosis Modulator Revenue by Country (2018-2023)
8.2 Middle East & Africa Oncology Apoptosis Modulator Sales By Apoptotic Pathway
8.3 Middle East & Africa Oncology Apoptosis Modulator Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oncology Apoptosis Modulator
10.3 Manufacturing Process Analysis of Oncology Apoptosis Modulator
10.4 Industry Chain Structure of Oncology Apoptosis Modulator
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oncology Apoptosis Modulator Distributors
11.3 Oncology Apoptosis Modulator Customer
12 World Forecast Review for Oncology Apoptosis Modulator by Geographic Region
12.1 Global Oncology Apoptosis Modulator Market Size Forecast by Region
12.1.1 Global Oncology Apoptosis Modulator Forecast by Region (2024-2029)
12.1.2 Global Oncology Apoptosis Modulator Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oncology Apoptosis Modulator Forecast By Apoptotic Pathway
12.7 Global Oncology Apoptosis Modulator Forecast by Application
13 Key Players Analysis
13.1 EpiCept Corporation
13.1.1 EpiCept Corporation Company Information
13.1.2 EpiCept Corporation Oncology Apoptosis Modulator Product Portfolios and Specifications
13.1.3 EpiCept Corporation Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 EpiCept Corporation Main Business Overview
13.1.5 EpiCept Corporation Latest Developments
13.2 Novartis Ltd.
13.2.1 Novartis Ltd. Company Information
13.2.2 Novartis Ltd. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.2.3 Novartis Ltd. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Novartis Ltd. Main Business Overview
13.2.5 Novartis Ltd. Latest Developments
13.3 Pfizer Inc.
13.3.1 Pfizer Inc. Company Information
13.3.2 Pfizer Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.3.3 Pfizer Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Pfizer Inc. Main Business Overview
13.3.5 Pfizer Inc. Latest Developments
13.4 Pharmacyclics, Inc.
13.4.1 Pharmacyclics, Inc. Company Information
13.4.2 Pharmacyclics, Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.4.3 Pharmacyclics, Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pharmacyclics, Inc. Main Business Overview
13.4.5 Pharmacyclics, Inc. Latest Developments
13.5 ISIS Pharmaceutical Inc.
13.5.1 ISIS Pharmaceutical Inc. Company Information
13.5.2 ISIS Pharmaceutical Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.5.3 ISIS Pharmaceutical Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 ISIS Pharmaceutical Inc. Main Business Overview
13.5.5 ISIS Pharmaceutical Inc. Latest Developments
13.6 Abbott Laboratories
13.6.1 Abbott Laboratories Company Information
13.6.2 Abbott Laboratories Oncology Apoptosis Modulator Product Portfolios and Specifications
13.6.3 Abbott Laboratories Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Abbott Laboratories Main Business Overview
13.6.5 Abbott Laboratories Latest Developments
13.7 Genta Inc.
13.7.1 Genta Inc. Company Information
13.7.2 Genta Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.7.3 Genta Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Genta Inc. Main Business Overview
13.7.5 Genta Inc. Latest Developments
13.8 Amgen Inc.
13.8.1 Amgen Inc. Company Information
13.8.2 Amgen Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.8.3 Amgen Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Amgen Inc. Main Business Overview
13.8.5 Amgen Inc. Latest Developments
13.9 Anavex Life Sciences Corporation
13.9.1 Anavex Life Sciences Corporation Company Information
13.9.2 Anavex Life Sciences Corporation Oncology Apoptosis Modulator Product Portfolios and Specifications
13.9.3 Anavex Life Sciences Corporation Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Anavex Life Sciences Corporation Main Business Overview
13.9.5 Anavex Life Sciences Corporation Latest Developments
13.10 Infinity Pharmaceuticals Inc.
13.10.1 Infinity Pharmaceuticals Inc. Company Information
13.10.2 Infinity Pharmaceuticals Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.10.3 Infinity Pharmaceuticals Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Infinity Pharmaceuticals Inc. Main Business Overview
13.10.5 Infinity Pharmaceuticals Inc. Latest Developments
13.11 ArQule Inc.
13.11.1 ArQule Inc. Company Information
13.11.2 ArQule Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.11.3 ArQule Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 ArQule Inc. Main Business Overview
13.11.5 ArQule Inc. Latest Developments
13.12 EntreMed Inc.
13.12.1 EntreMed Inc. Company Information
13.12.2 EntreMed Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.12.3 EntreMed Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 EntreMed Inc. Main Business Overview
13.12.5 EntreMed Inc. Latest Developments
13.13 Theraptosis SA
13.13.1 Theraptosis SA Company Information
13.13.2 Theraptosis SA Oncology Apoptosis Modulator Product Portfolios and Specifications
13.13.3 Theraptosis SA Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Theraptosis SA Main Business Overview
13.13.5 Theraptosis SA Latest Developments
13.14 ApopLogic Pharmaceuticals Inc
13.14.1 ApopLogic Pharmaceuticals Inc Company Information
13.14.2 ApopLogic Pharmaceuticals Inc Oncology Apoptosis Modulator Product Portfolios and Specifications
13.14.3 ApopLogic Pharmaceuticals Inc Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 ApopLogic Pharmaceuticals Inc Main Business Overview
13.14.5 ApopLogic Pharmaceuticals Inc Latest Developments
14 Research Findings and Conclusion

　

ページTOPに戻る


　

Summary

The global Oncology Apoptosis Modulator market size is projected to grow from US$ 3815.2 million in 2022 to US$ 8128.5 million in 2029; it is expected to grow at a CAGR of 11.4% from 2023 to 2029.
United States market for Oncology Apoptosis Modulator is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Oncology Apoptosis Modulator is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Oncology Apoptosis Modulator is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Oncology Apoptosis Modulator players cover EpiCept Corporation, Novartis Ltd., Pfizer Inc., Pharmacyclics, Inc., ISIS Pharmaceutical Inc., Abbott Laboratories, Genta Inc., Amgen Inc. and Anavex Life Sciences Corporation, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Oncology Apoptosis Modulator is a BH3-like protein that plays key roles in cell death or apoptosis. It is an integral partner to the tumor suppressor protein, Ras association domain family 1A (RASSF1A), and functions to activate the Bcl-2 family pro-apoptotic protein Bax.
LPI (LP Information)' newest research report, the “Oncology Apoptosis Modulator Industry Forecast” looks at past sales and reviews total world Oncology Apoptosis Modulator sales in 2022, providing a comprehensive analysis by region and market sector of projected Oncology Apoptosis Modulator sales for 2023 through 2029. With Oncology Apoptosis Modulator sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Oncology Apoptosis Modulator industry.
This Insight Report provides a comprehensive analysis of the global Oncology Apoptosis Modulator landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Oncology Apoptosis Modulator portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Oncology Apoptosis Modulator market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Oncology Apoptosis Modulator and breaks down the forecast by apoptotic pathway, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Oncology Apoptosis Modulator.
This report presents a comprehensive overview, market shares, and growth opportunities of Oncology Apoptosis Modulator market by product apoptotic pathway, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by apoptotic pathway
Extrinsic Pathway
Intrinsic Pathway
Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
EpiCept Corporation
Novartis Ltd.
Pfizer Inc.
Pharmacyclics, Inc.
ISIS Pharmaceutical Inc.
Abbott Laboratories
Genta Inc.
Amgen Inc.
Anavex Life Sciences Corporation
Infinity Pharmaceuticals Inc.
ArQule Inc.
EntreMed Inc.
Theraptosis SA
ApopLogic Pharmaceuticals Inc
Key Questions Addressed in this Report
What is the 10-year outlook for the global Oncology Apoptosis Modulator market?
What factors are driving Oncology Apoptosis Modulator market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Oncology Apoptosis Modulator market opportunities vary by end market size?
How does Oncology Apoptosis Modulator break out apoptotic pathway, application?
What are the influences of COVID-19 and Russia-Ukraine war?



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Oncology Apoptosis Modulator Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Oncology Apoptosis Modulator by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Oncology Apoptosis Modulator by Country/Region, 2018, 2022 & 2029
2.2 Oncology Apoptosis Modulator Segment By Apoptotic Pathway
2.2.1 Extrinsic Pathway
2.2.2 Intrinsic Pathway
2.3 Oncology Apoptosis Modulator Sales By Apoptotic Pathway
2.3.1 Global Oncology Apoptosis Modulator Sales Market Share By Apoptotic Pathway (2018-2023)
2.3.2 Global Oncology Apoptosis Modulator Revenue and Market Share By Apoptotic Pathway (2018-2023)
2.3.3 Global Oncology Apoptosis Modulator Sale Price By Apoptotic Pathway (2018-2023)
2.4 Oncology Apoptosis Modulator Segment by Application
2.4.1 Hospital Pharmacies
2.4.2 Retail Pharmacies
2.4.3 Online Pharmacies
2.5 Oncology Apoptosis Modulator Sales by Application
2.5.1 Global Oncology Apoptosis Modulator Sale Market Share by Application (2018-2023)
2.5.2 Global Oncology Apoptosis Modulator Revenue and Market Share by Application (2018-2023)
2.5.3 Global Oncology Apoptosis Modulator Sale Price by Application (2018-2023)
3 Global Oncology Apoptosis Modulator by Company
3.1 Global Oncology Apoptosis Modulator Breakdown Data by Company
3.1.1 Global Oncology Apoptosis Modulator Annual Sales by Company (2018-2023)
3.1.2 Global Oncology Apoptosis Modulator Sales Market Share by Company (2018-2023)
3.2 Global Oncology Apoptosis Modulator Annual Revenue by Company (2018-2023)
3.2.1 Global Oncology Apoptosis Modulator Revenue by Company (2018-2023)
3.2.2 Global Oncology Apoptosis Modulator Revenue Market Share by Company (2018-2023)
3.3 Global Oncology Apoptosis Modulator Sale Price by Company
3.4 Key Manufacturers Oncology Apoptosis Modulator Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Oncology Apoptosis Modulator Product Location Distribution
3.4.2 Players Oncology Apoptosis Modulator Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Oncology Apoptosis Modulator by Geographic Region
4.1 World Historic Oncology Apoptosis Modulator Market Size by Geographic Region (2018-2023)
4.1.1 Global Oncology Apoptosis Modulator Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Oncology Apoptosis Modulator Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Oncology Apoptosis Modulator Market Size by Country/Region (2018-2023)
4.2.1 Global Oncology Apoptosis Modulator Annual Sales by Country/Region (2018-2023)
4.2.2 Global Oncology Apoptosis Modulator Annual Revenue by Country/Region (2018-2023)
4.3 Americas Oncology Apoptosis Modulator Sales Growth
4.4 APAC Oncology Apoptosis Modulator Sales Growth
4.5 Europe Oncology Apoptosis Modulator Sales Growth
4.6 Middle East & Africa Oncology Apoptosis Modulator Sales Growth
5 Americas
5.1 Americas Oncology Apoptosis Modulator Sales by Country
5.1.1 Americas Oncology Apoptosis Modulator Sales by Country (2018-2023)
5.1.2 Americas Oncology Apoptosis Modulator Revenue by Country (2018-2023)
5.2 Americas Oncology Apoptosis Modulator Sales By Apoptotic Pathway
5.3 Americas Oncology Apoptosis Modulator Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Oncology Apoptosis Modulator Sales by Region
6.1.1 APAC Oncology Apoptosis Modulator Sales by Region (2018-2023)
6.1.2 APAC Oncology Apoptosis Modulator Revenue by Region (2018-2023)
6.2 APAC Oncology Apoptosis Modulator Sales By Apoptotic Pathway
6.3 APAC Oncology Apoptosis Modulator Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Oncology Apoptosis Modulator by Country
7.1.1 Europe Oncology Apoptosis Modulator Sales by Country (2018-2023)
7.1.2 Europe Oncology Apoptosis Modulator Revenue by Country (2018-2023)
7.2 Europe Oncology Apoptosis Modulator Sales By Apoptotic Pathway
7.3 Europe Oncology Apoptosis Modulator Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Oncology Apoptosis Modulator by Country
8.1.1 Middle East & Africa Oncology Apoptosis Modulator Sales by Country (2018-2023)
8.1.2 Middle East & Africa Oncology Apoptosis Modulator Revenue by Country (2018-2023)
8.2 Middle East & Africa Oncology Apoptosis Modulator Sales By Apoptotic Pathway
8.3 Middle East & Africa Oncology Apoptosis Modulator Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Oncology Apoptosis Modulator
10.3 Manufacturing Process Analysis of Oncology Apoptosis Modulator
10.4 Industry Chain Structure of Oncology Apoptosis Modulator
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Oncology Apoptosis Modulator Distributors
11.3 Oncology Apoptosis Modulator Customer
12 World Forecast Review for Oncology Apoptosis Modulator by Geographic Region
12.1 Global Oncology Apoptosis Modulator Market Size Forecast by Region
12.1.1 Global Oncology Apoptosis Modulator Forecast by Region (2024-2029)
12.1.2 Global Oncology Apoptosis Modulator Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Oncology Apoptosis Modulator Forecast By Apoptotic Pathway
12.7 Global Oncology Apoptosis Modulator Forecast by Application
13 Key Players Analysis
13.1 EpiCept Corporation
13.1.1 EpiCept Corporation Company Information
13.1.2 EpiCept Corporation Oncology Apoptosis Modulator Product Portfolios and Specifications
13.1.3 EpiCept Corporation Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 EpiCept Corporation Main Business Overview
13.1.5 EpiCept Corporation Latest Developments
13.2 Novartis Ltd.
13.2.1 Novartis Ltd. Company Information
13.2.2 Novartis Ltd. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.2.3 Novartis Ltd. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Novartis Ltd. Main Business Overview
13.2.5 Novartis Ltd. Latest Developments
13.3 Pfizer Inc.
13.3.1 Pfizer Inc. Company Information
13.3.2 Pfizer Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.3.3 Pfizer Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Pfizer Inc. Main Business Overview
13.3.5 Pfizer Inc. Latest Developments
13.4 Pharmacyclics, Inc.
13.4.1 Pharmacyclics, Inc. Company Information
13.4.2 Pharmacyclics, Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.4.3 Pharmacyclics, Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Pharmacyclics, Inc. Main Business Overview
13.4.5 Pharmacyclics, Inc. Latest Developments
13.5 ISIS Pharmaceutical Inc.
13.5.1 ISIS Pharmaceutical Inc. Company Information
13.5.2 ISIS Pharmaceutical Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.5.3 ISIS Pharmaceutical Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 ISIS Pharmaceutical Inc. Main Business Overview
13.5.5 ISIS Pharmaceutical Inc. Latest Developments
13.6 Abbott Laboratories
13.6.1 Abbott Laboratories Company Information
13.6.2 Abbott Laboratories Oncology Apoptosis Modulator Product Portfolios and Specifications
13.6.3 Abbott Laboratories Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Abbott Laboratories Main Business Overview
13.6.5 Abbott Laboratories Latest Developments
13.7 Genta Inc.
13.7.1 Genta Inc. Company Information
13.7.2 Genta Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.7.3 Genta Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Genta Inc. Main Business Overview
13.7.5 Genta Inc. Latest Developments
13.8 Amgen Inc.
13.8.1 Amgen Inc. Company Information
13.8.2 Amgen Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.8.3 Amgen Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Amgen Inc. Main Business Overview
13.8.5 Amgen Inc. Latest Developments
13.9 Anavex Life Sciences Corporation
13.9.1 Anavex Life Sciences Corporation Company Information
13.9.2 Anavex Life Sciences Corporation Oncology Apoptosis Modulator Product Portfolios and Specifications
13.9.3 Anavex Life Sciences Corporation Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Anavex Life Sciences Corporation Main Business Overview
13.9.5 Anavex Life Sciences Corporation Latest Developments
13.10 Infinity Pharmaceuticals Inc.
13.10.1 Infinity Pharmaceuticals Inc. Company Information
13.10.2 Infinity Pharmaceuticals Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.10.3 Infinity Pharmaceuticals Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Infinity Pharmaceuticals Inc. Main Business Overview
13.10.5 Infinity Pharmaceuticals Inc. Latest Developments
13.11 ArQule Inc.
13.11.1 ArQule Inc. Company Information
13.11.2 ArQule Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.11.3 ArQule Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 ArQule Inc. Main Business Overview
13.11.5 ArQule Inc. Latest Developments
13.12 EntreMed Inc.
13.12.1 EntreMed Inc. Company Information
13.12.2 EntreMed Inc. Oncology Apoptosis Modulator Product Portfolios and Specifications
13.12.3 EntreMed Inc. Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 EntreMed Inc. Main Business Overview
13.12.5 EntreMed Inc. Latest Developments
13.13 Theraptosis SA
13.13.1 Theraptosis SA Company Information
13.13.2 Theraptosis SA Oncology Apoptosis Modulator Product Portfolios and Specifications
13.13.3 Theraptosis SA Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Theraptosis SA Main Business Overview
13.13.5 Theraptosis SA Latest Developments
13.14 ApopLogic Pharmaceuticals Inc
13.14.1 ApopLogic Pharmaceuticals Inc Company Information
13.14.2 ApopLogic Pharmaceuticals Inc Oncology Apoptosis Modulator Product Portfolios and Specifications
13.14.3 ApopLogic Pharmaceuticals Inc Oncology Apoptosis Modulator Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 ApopLogic Pharmaceuticals Inc Main Business Overview
13.14.5 ApopLogic Pharmaceuticals Inc Latest Developments
14 Research Findings and Conclusion

　

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（バイオ薬物）の最新刊レポート

LP Information 社の最新刊レポート

本レポートと同じKEY WORD（oncology）の最新刊レポート


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

お問合せはこちらから

03-3582-2531

電話お問合せもお気軽に

 

2024/11/08　10:26

154.13 円

166.76 円

202.76 円

ページTOPに戻る

株式会社 データリソース　Data Resources, Inc.
東京都港区赤坂1-14-5　アークヒルズエグゼクティブタワー N313

電話：03-3582-2531
FAX：03-3582-2861
Eメール：office@dri.co.jp

FAQ サイトマップ プライバシーポリシー お問合せ

関連会社:
株式会社ユーディーアール

COPYRIGHT(C) 2011-2023　DATA RESOURCES, Inc. ALL RIGHTS RESERVED.